Premium
IC‐P‐086: Amyloid‐β and Hyperphosphorylated TAU Synergy Drives Clinical Progression to Alzheimer’s Disease
Author(s) -
Pascoal Tharick A.,
Mathotaarachchi Sulantha S.,
Shin Monica,
Benedet Andrea Lessa,
Kang Min Su,
Mohades Sara,
Beaudry Thomas,
Soucy Jean-Paul,
Gauthier Serge,
Rosa-Neto Pedro
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.115
Subject(s) - dementia , neuropsychology , medicine , oncology , psychology , positron emission tomography , clinical dementia rating , biomarker , voxel , logistic regression , cognition , neuroscience , disease , biology , radiology , biochemistry
(Figure 3). Finally, a statistical conjunction analysis revealed significant hypometabolism across all FTD syndromes in the left frontal operculum and dorsomedial prefrontal cortex at follow-up but not at baseline. Conclusions:This study highlighted specific patterns of metabolic change over time in each variant, with both increased local hypometabolism, as well as extension into new regions. In agreement with clinical convergence, the syndromes also showed increased similarity in their hypometabolic patterns with time. Altogether, our result suggests that FDG-PET is a sensitive biomarker for tracking disease progression in FTD.